Latest Medical Devices News

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.

ImpediMed Limited reported a record A$3.4 million revenue in Q3 FY25, bolstered by a surge in Annual Recurring Revenue and a strategic sales leadership change aimed at accelerating SOZO platform adoption.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Desane Group Holdings has secured a seven-year lease extension with Signature Orthopaedics at its Lane Cove property, guaranteeing $5 million in rental income through 2032. This deal reinforces Desane’s strategy to maintain stable medium-term cash flows.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.